Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than financial performance metrics.
Material Changes
The filing details a transaction where a Connected Person, Dr. S. Dexter, increased their holding of Ordinary Shares in GlaxoSmithKline plc. This increase resulted from the re-investment of a dividend paid on April 11, 2013, and the purchase of shares at a price of 1,577.0649 pence per share on April 12, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a specific insider transaction compliant with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: April 12, 2013.
- Connected Person: Dr. S. Dexter (Connected to Director Dr. P. J. T. Vallance).
- Shares Acquired: 169 Ordinary Shares.
- Share Price: 1,577.0649 pence per share.
- Transaction Type: Dividend re-investment and share purchase.
- Notification Date: April 25, 2013.